

## Special Issue

# CRLM in the Era of Transplant Oncology: New Hope, New Questions

### Message from the Guest Editors

Colorectal liver metastases (CRLM) remain one of the most challenging domains in oncologic surgery, with curative resection only available to a minority of patients. However, recent data, most notably from the TRANSMET study have brought new optimism. The demonstration of a survival benefit in selected patients with unresectable CRLM undergoing liver transplantation marks a potential paradigm shift in treatment strategy.

This emerging therapeutic avenue raises several pressing clinical and scientific questions. Should adjuvant or maintenance chemotherapy be continued post-transplant? Could liquid biopsy or circulating tumor DNA be leveraged for surveillance or patient selection? What are the ethical, logistical, and immunological considerations when transplanting patients with active malignancy?

Given this rapidly evolving landscape, we propose a Special Issue dedicated to CRLM, with a focus on cutting-edge developments in transplantation, systemic therapy, molecular stratification and post-treatment surveillance. The goal is to bring together surgical oncologists, hepatologists, transplant teams, medical oncologists, and molecular biologists to chart the future of CRLM management.

---

### Guest Editors

Prof. Dr. Brian Davidson  
Division of Surgery & Interventional Sciences, University College  
London, London, UK

Dr. Khurum Khan  
Department of Medical Oncology, University College London Hospitals  
NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK

---

### Deadline for manuscript submissions

30 September 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/255801](https://mdpi.com/si/255801)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)